Cite
HARVARD Citation
Kulke, M. et al. (2019). A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of oncology. p. 1846. [Online].